Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review

Background: Clozapine is the only Food and Drug Administration (FDA) and National Institute for Care and Excellence (NICE) approved drug for treatment-resistant schizophrenia (TRS). Its potentially life-threatening haematological side effects of neutropaenia and agranulocytosis mandate rigorous moni...

詳細記述

書誌詳細

主要な著者:	Michelle V. Daniels, Suvira Ramlall
フォーマット:	Artigo
言語:	Inglês
出版事項:	AOSIS 2023-10-01
シリーズ:	South African Journal of Psychiatry
主題:	clozapine monitoring guidelines clozapine monitoring guidelines in south africa treatment-resistant schizophrenia benign ethnic neutropaenia benign familial neutropaenia clozapine-induced neutropaenia clozapine-induced agranulocytosis
オンライン･アクセス:	https://sajp.org.za/index.php/sajp/article/view/2039
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!